Literature DB >> 19524354

Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.

Paramananthan Mariappan1, Alexandra Zachou, Kenneth M Grigor.   

Abstract

BACKGROUND: An European Organisation for Research and Treatment of Cancer analysis of multicentre trials found significant interinstitutional variability in recurrence rates at first follow-up cystoscopy (RR-FFC) and attributed this to variable transurethral resection of bladder tumour (TURBT) quality.
OBJECTIVE: To determine whether resection of detrusor muscle (DM) in the first, apparently complete TURBT is a surrogate marker of quality and whether the presence of DM is dependent on a surgeon's experience. DESIGN, SETTING, AND PARTICIPANTS: Over a 2-yr period, patients with new bladder tumours that were judged to have been completely resected were recruited from our prospectively maintained bladder tumour database. Strict exclusion criteria were applied. MEASUREMENTS: Prospectively recorded tumour size, tumour multiplicity, surgeon category, DM status, grade and stage of tumour, and findings at first follow-up cystoscopy (at 3 mo) and at early re-TURBT were evaluated. Surgeons were stratified into seniors (consultants and year 5 or year 6 trainees) and juniors (trainees lower than year 5). Early recurrence (for calculating RR-FFC) was defined as pathologically confirmed tumour on early re-TURBT or recurrence at the first follow-up cystoscopy. Logistic regression multivariate analyses were carried out to determine associations between variables. RESULTS AND LIMITATIONS: In a total of 356 patients, DM was present in 241 patients (67.7%). Multivariate analyses revealed that large tumours, high-grade tumours, and surgery by senior surgeons was independently associated with the presence of DM in the resected specimens. The RR-FFCs when DM was absent and present were 44.4% and 21.7%, respectively (odds ratio: 2.9; 95% confidence interval: 1.6-5.4; p=0.0002). The absence of DM and resection by less experienced surgeons independently predicted a higher RR-FFC. This association was also seen in small and low-grade tumours. The number of patients in this study appears modest, and further validation may be required.
CONCLUSIONS: DM absence or presence in the first, apparently complete TURBT specimen appears to be a surrogate marker of resection quality by independently predicting the RR-FFC, which is also dependent on surgeon experience.
Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524354     DOI: 10.1016/j.eururo.2009.05.047

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  56 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 2.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

Review 3.  [En bloc resection and vaporization techniques for the treatment of bladder cancer].

Authors:  J P Struck; A Karl; C Schwentner; T R W Herrmann; M W Kramer
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

Review 4.  [Transurethral en bloc resection of non-muscle invasive bladder cancer. What is the state of the art?].

Authors:  M W Kramer; M Wolters; I F Abdelkawi; A S Merseburger; U Nagele; A Gross; T Bach; M A Kuczyk; T R W Herrmann
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

5.  Transurethral En Bloc Resection of Bladder Tumor Using an Endoscopic Submucosal Dissection Technique: Preliminary Results in an Animal Model.

Authors:  Shuichi Morizane; Takehiro Sejima; Hideto Iwamoto; Toshihiko Masago; Masashi Honda; Yuichiro Ikebuchi; Kazuya Matsumoto; Masaru Ueki; Atsushi Takenaka
Journal:  Yonago Acta Med       Date:  2016-06-29       Impact factor: 1.641

Review 6.  [Transurethral resection of bladder tumors: management of complications].

Authors:  S Rausch; G Gakis; A Stenzl
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

Review 7.  Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies.

Authors:  Daniel Zainfeld; Siamak Daneshmand
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

Review 8.  Diagnosis and management of intradiverticular bladder tumours.

Authors:  Nicholas Faure Walker; Christine Gan; Jonathon Olsburgh; Muhammad Shamim Khan
Journal:  Nat Rev Urol       Date:  2014-06-17       Impact factor: 14.432

Review 9.  Approaching the optimal transurethral resection of a bladder tumor.

Authors:  Michael Jurewicz; Mark S Soloway
Journal:  Turk J Urol       Date:  2014-06

10.  Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC).

Authors:  Tetsuya Shindo; Naoya Masumori; Hiroshi Kitamura; Toshiaki Tanaka; Fumimasa Fukuta; Tadashi Hasegawa; Masahiro Yanase; Masafumi Miyake; Noriomi Miyao; Atsushi Takahashi; Masanori Matsukawa; Keisuke Taguchi; Masanori Shigyo; Yasuharu Kunishima; Hitoshi Tachiki; Taiji Tsukamoto
Journal:  World J Urol       Date:  2013-11-05       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.